Brokerages expect Advaxis, Inc. (NASDAQ:ADXS) to announce earnings of ($1.49) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Advaxis’ earnings, with the lowest EPS estimate coming in at ($1.80) and the highest estimate coming in at ($1.19). Advaxis reported earnings of ($4.03) per share in the same quarter last year, which indicates a positive year over year growth rate of 63%. The business is scheduled to issue its next earnings results on Thursday, June 6th.
According to Zacks, analysts expect that Advaxis will report full-year earnings of ($2.40) per share for the current financial year. For the next year, analysts forecast that the company will post earnings of ($2.95) per share, with EPS estimates ranging from ($3.60) to ($2.30). Zacks’ EPS averages are an average based on a survey of analysts that cover Advaxis.
Advaxis (NASDAQ:ADXS) last posted its earnings results on Tuesday, March 12th. The biotechnology company reported $0.18 EPS for the quarter, beating the consensus estimate of ($0.25) by $0.43. The firm had revenue of $19.69 million for the quarter. Advaxis had a negative return on equity of 101.51% and a negative net margin of 140.12%.
Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC increased its stake in Advaxis by 740.4% during the 4th quarter. Virtu Financial LLC now owns 176,213 shares of the biotechnology company’s stock worth $33,000 after buying an additional 155,246 shares during the period. Two Sigma Investments LP increased its stake in Advaxis by 2,468.2% during the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after buying an additional 355,415 shares during the period. Deutsche Bank AG increased its stake in Advaxis by 5,970.3% during the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares during the period. Renaissance Technologies LLC increased its stake in Advaxis by 173.0% during the 3rd quarter. Renaissance Technologies LLC now owns 1,191,846 shares of the biotechnology company’s stock worth $1,120,000 after buying an additional 755,352 shares during the period. Finally, BlackRock Inc. increased its stake in Advaxis by 3.1% during the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after buying an additional 43,368 shares during the period.
NASDAQ:ADXS traded down $0.15 during trading hours on Wednesday, hitting $3.40. The company’s stock had a trading volume of 15,940 shares, compared to its average volume of 1,181,754. The firm has a market capitalization of $19.34 million, a PE ratio of -0.18 and a beta of 3.95. Advaxis has a 52-week low of $2.70 and a 52-week high of $30.60.
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.